• Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact

Barry A. Friedman, PhD LLC

FDA Regulatory Compliance for the Pharmaceutical, Biotechnology and Medical Device Arenas

General Chapter (USP<60>) on B. cepacia Complex to Issue December 1, 2019

February 19, 2019 By Barry Friedman Leave a Comment

Pharmacopeial Forum (PF, September/October 2018, 44(5)) published a new, proposed General Chapter (USP<60>) on B. cepacia Complex entitled “USP<60> Microbiological Examination of Nonsterile Products—Tests for Burkholderia cepacia Complex”.  The proposed PF chapter represents an expansion of USP<62> Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms. It is planned to issue as USP<60> on Dececmber 1, 2019.

Because USP<62> is a harmonized chapter with the European Union and Japan, the USP Microbiological Expert Committee recognized it would be difficult and time consuming to modify it to address the B. cepacia Complex (BCC) issue.  At the same time the USP Microbiological Expert Committee recognized that USP<62> was inadequate for determining the presence/absence of the BCC which is often a contaminant of water, preserved aqueous and oral liquids, and topical products..

This new Chapter is designed as an extension of USP<61>/<62> General Chapters and to increase the probability of detection of the BCC over the current methods described in USP<62>. While this Chapter will not provide for speciation of the BCC, it will provide methodology to provide a presumptive identification based upon verification/qualification.

Genotypic methods are available today that will provide speciation for as many as 23 different  microorganisms within the BCC, but require more effort than the initial 500 base pairs available with the 16s rRNA.  The newer technology emphasizes the use of recA to identify the microorganisms within this BCC “cluster”.

Please plan to attend one of my upcoming webinars which can be found at ECCWebinars.com or Pharmawebinars.com to learn about the latest updates and identification methodologies.

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)

Related

Filed Under: FDA Compliance, Microbiological Issues, Regulatory Compliance Tagged With: BCC, genotypic, identification, PF, recA, rRNA, USP, USP. B. cepacia

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

New Reader? Learn More

Connect With Me:

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Webinar Registration & Information

FREQUENTLY ASKED QUESTIONS:

FDA Form 483 Frequently Asked Questions

USP General Chapter

USP General Chapter 62, Part II

TOP OBSERVATIONS:

FDA’s CDER LISTING OF TOP NINETEEN OBSERVATIONS FOR 2014

FDA CDER Most Frequent Form FDA 483 Observations Fiscal Year 2012

CDER MOST FREQUENTLY CITED DRUG OBSERVATIONS – FISCAL YEAR 2010

Top Posts:

Top Posts for 2012

Top Posts for 2013

Top Posts Year To Date

Recent Posts

  • Upcoming Microbiological Webinars
  • Microbiological Webinars
  • Microbiological Webinars 2020 (Upcoming)
  • General Chapter (USP<60>) on B. cepacia Complex to Issue December 1, 2019
  • Les Produits Chimiques B.G.R., Inc. Receives FDA Warning Letter (07/24/2018) for Failure to Perform Laboratory Testing

Categories

follow us in feedly
  • Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Thank You For Visiting Barry A. Friedman, PhD LLC - 2015

Welcome To My Blog!
Please enter your name and email below to receive my newsletter.
Your information will *never* be shared or sold to a 3rd party.